Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax
Insights in Blood Disorders · 2022
DOI: 10.33425/2771-9073.1007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Insights in Blood Disorders, 2022. Verfasst von Mamaev NN und 8 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Clinical and laboratory data are presented of a 29 year female patient with BAALC- and BCL-2-positive T-cell acute lymphoblastic leukemia developed from early leukemic progenitors which was treated unsuccessfully with high-dose chemotherapy and allogeneic stem cell transplant (allo-HSCT), but revealed an impressive effect of venetoclax. For reasons beyond our control, allo-HSCT with myeloablative fludarabine-busulfan (14 mg/ kg) conditioning regimen was performed at the peak of relapse when blast count in bone marrow aspirate was 77.5%, whereas level of BAALC-expressing earlier progenitors (EP) reached 186%. HSCT was ineffective, since the number of blasts on day+30 reached 86%, whereas the burden of BAALC-expressing EP decreased to the cutoff values. Later, at post-transplant stage, an impressive response to venetoclax coupled with hypomethylating agent was observed. Following allo-HSCT and combined venetoclax therapy a severe pancytopenia developed, which required the second transplantation of peripheral blood stem cells from her haplo-matched father. After transplantation hematopoietic recovery started on day 10+. Although bone marrow aspirate at this point was hypo cellular, it contained all types of granulocytic and erythroid elements and 2.2% of blasts only.
Zitieren
APA
NN, M., VV, B., AI, S., MM, K., EV, B., IS, M., OS, U., JJ, V., & SN, B. (2022). Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax. Insights in Blood Disorders. https://doi.org/10.33425/2771-9073.1007
Vancouver
NN M, VV B, AI S, MM K, EV B, IS M, et al. Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax. Insights in Blood Disorders. 2022. doi:10.33425/2771-9073.1007
BibTeX
@article{NN2022,
author = {NN, Mamaev and VV, Baykov and AI, Shakirova and MM, Kanunnikov and EV, Babenko and IS, Martynkevich and OS, Uspenskaya and JJ, Vlasova and SN, Bondarenko},
title = {Near-Early T-Cell ALL with Overexpression of BAALC and BCL-2 Genes, Non-Responsive to High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation, but with Impressive Response to Venetoclax},
journal = {Insights in Blood Disorders},
year = {2022},
doi = {10.33425/2771-9073.1007}
}
EUVIMED